Patents (1436 Stem Cell Patents)

Patents

Order by:
<< | < | 1 2 3 4 5 6 | > | >>


Compositions, systems and methods for treatment of defects in blood vessels

Patent Number: 7,201,918
Vascular aneurysms are thinning of blood vessel walls, which is usually associated with vessel trauma, non-specific degeneration, atherosclerosis, or infection. The term "aneurysm" comes from the Latin "aneurysma" which means "dilation". Aneurysms are hazardous because of the potential to burst. They are usually prevelant in the aorta or cerebral arteries. The current patent provides methods...
Inventors: Cruise; Gregory M. (Rancho Santa Margarita, CA)
Assignee: Microvention, Inc. (Aliso Viejo, CA)
Date of First Priority Issue: Tuesday November 16th, 2004

Clusterin-mediated inhibition of apoptosis via stromal bone marrow cell delivery to a cardiac site

Patent Number: 7,524,490
 Many diseases are associated with either too much apoptosis (eg ALS, Parkinson's, Liver failure, etc) or too little apoptosis (cancer).  The current patent covers a method to suppress apoptosis in mammalian cells.The method consists of transfecting an isolated population bone marrow derived stromal cells (either autologous or allogeneic) with a nucleic acid encoding the clusterin...
Inventors: Geng; Yong-Jian (Pearland, TX)
Assignee: Board of Regents The University of Texas (Austin, TX)
Date of First Priority Issue: Wednesday November 10th, 2004

Neuronal progenitors from feeder-free human embryonic stem cell culture

Patent Number: 7,531,354
This patent covers methods of generating neural progenitor cells from embryonic stem cells in absence of feeder cells.  Other patents exist that cover feeder-free technology, or technologies using non-mouse feeder cells.  The current patent covers the generation of the neural progenitors by:a. contacting adherent primate...
Inventors: Stice; Steve (Athens, GA), Shin; Soojung (Baltimore, MD), Dhara; Sujoy (Athens, GA)
Assignee: University of Georgia Research Foundation, Inc. (Athens, GA)
Date of First Priority Issue: Tuesday October 5th, 2004

Cord blood and placenta collection kit

Patent Number: 7,147,626
Celgene, through its wholly owned subsiduary Anthrogenesis (now called Celgene Cellular Therapeutics) has been active in the cord blood IP area, through patents covering innovative methods of extracting stem cells from the placental matrix itself . In the current patent, Celgene covers a kit for collecting not only the umbilical...
Inventors: Goodman; Chris B. (Green Brook, NJ), Robinson; Wayne Malcolm (Hampton, NJ), Feingold; Barnett Dov (New York, NY)
Assignee: Celgene Corporation (Summit, NJ)
Date of First Priority Issue: Thursday September 23rd, 2004 5 Comments

Culturing human embryonic stem cells in medium containing pipecholic acid and gamma amino butyric acid

Patent Number: 7,442,548
This patent covers new types of media useful for expansion of embryonic stem cells in absence of feeder cells or supernatant of other cells (conditioned media).  The patent essentially covers the use of various concentrations of albumin, minerals, vitamins, amino acids, glucose, a fibroblast growth factor, gamma amino butyric acid, pipecholic acid, lithium, lipids, a transferrin or a...
Inventors: Thomson; James A. (Madison, WI), Ludwig; Tenneille (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Date of First Priority Issue: Wednesday September 8th, 2004

Musculo-skeletal implant having a bioactive gradient

Patent Number: 7,351,423
It is known that stem cells migrate towards injured tissue in response to chemotactic gradients.  For example the basal SDF-1 gradient made by bone marrow stromal cells is why it is possible to achieve hematopoietic reconstitution by injecting donor cells intravenously.  Similarly, SDF-1 acts as a gradient to call stem cells into damaged myocardium after a...
Inventors: Kadiyala; Sudhakar (Newton, MA), Binette; Francois (Weymouth, MA), Coleman; Cynthia Marie (Brookline, MA), Kapur; Theresa Adams (Stoughton, MA)
Assignee: Depuy Spine, Inc. (Raynham, MA)
Date of First Priority Issue: Wednesday September 1st, 2004

Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity

Patent Number: 7,241,812
It is known that Sphingosine-1-phosphate mediates migration of mesenchymal stem cells. However, there are numerous receptors by which the effects of sphingosine-1-phosphate are mediated. While the sphingosine-1-phosphate receptor 1 is associated with migration, other activation of other receptors (such as sphingosine-1-phosphate receptors...
Inventors: Saha; Ashis K. (Stow, MA), Kavarana; Malcolm J. (Burlington, MA), Evindar; Ghotas (Waltham, MA), Satz; Alexander L. (Needham, MA), Morgan; Barry (Franklin, MA)
Assignee: Praecis Pharmaceuticals, Inc. (Waltham, MA)
Date of First Priority Issue: Friday August 13th, 2004

Methods for identifying stem cells based on nuclear morphotypes

Patent Number: 7,427,502
Stem cells are usually identified based on markers such as CD34 for hematopoietic stem cells, or CD133 for cancer stem cells, or specific properties such as expression of aldehyde dehydrogenase.  Interestingly, in this patent the morphological characteristics of the stem cell are covered !The first...
Inventors: Gostjeva; Elena V. (Winchester, MA), Thilly; William G. (Winchester, MA)
Assignee: Massachusetts Institute of Technology (Cambridge, MA)
Date of First Priority Issue: Thursday June 17th, 2004

Compounds modulating c-kit activity

Patent Number: 7,498,342
c-kit is involved in hematopoietic stem cell self-renewal, however it is also found in other stem cells as well.  For example, cardiac stem cells express c-kit.  This is an exciting drug target and other companies have patents covering its inhibitors, for example, #7,211,600 by Sugen.The current patent covers composition of...
Inventors: Ibrahim; Prabha N. (Mountain View, CA), Hurt; Clarence R. (San Ramon, CA), Zhang; Chao (Moraga, CA), Zhang; Jiazhong (Oakland, CA)
Assignee: Plexxikon, Inc. (Berkeley, CA)
Date of First Priority Issue: Thursday June 17th, 2004

Genome mutation by intron insertion into an embryonic stem cell genome

Patent Number: 7,205,148
Genetic manipulation of ES cells provides a powerful method for developing unique cell line models of various human diseases. More clinically applicable is the possibility of specifically producing mutations in genes that elicit rejection of ES cells, so as to generate "universal donor" stem cells. This patent teaches ways of generating mutations in exons of genes in ES cells by introduction...
Inventors: Economides; Aris N. (Tarrytown, NY), Valenzuela; David M. (Yorktown Heights, NY), Davis; Samuel (New York, NY), Yancopoulos; George (Yorktown Heights, NY)
Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Date of First Priority Issue: Thursday June 10th, 2004

Transgenic pigs carrying both hHO-1 and hDAF transgenes for xenotransplantation

Patent Number: 7,378,569
Xenotransplantation offers the possibility of using animal organs either permanently as a substitute for human organs, or as a "bridge" until a suitable human organ may be found.  The most significant barriers to xenotransplantation appear to be innate in nature.  Specifically, the first barrier is the hyperacute rejection, which occurs because of a very high level of preformed...
Inventors: Tu; Ching-Fu (Miaoli Hsien, TW), Yang; Chi-Kai (Miaoli Hsien, TW), Liu; Ming-Shing (Miaoli Hsien, TW), Ho; Lin-Lin (Miaoli Hsien, TW), Huang; Kuei-Feng (Miaoli Hsien, TW), Lee; Chun-Jean (Miaoli Hsien, TW), Tai; Hao-Chih (Miaoli Hsien, TW)
Assignee: Animal Technology Institute Taiwan (TW)
Date of First Priority Issue: Tuesday June 1st, 2004

Feeder independent extended culture of embryonic stem cells

Patent Number: 7,514,260
This patent covers methods of expanding embryonic stem cells without inducing their differentiation.  It specifically teaches feeder-free systems so that exogenous cells do not need to be used.It gets away without needing a feeder by providing 2 cytokines:noggin, and a fibroblast growth factor family member, as well as various nutrients.The first independent claim is: "A method...
Inventors: Xu; Ren-He (Madison, WI), Thomson; James A. (Madison, WI)
Assignee: WiCell Research Institute, Inc. (Madison, WI)
Date of First Priority Issue: Friday May 21st, 2004

Pluripotent adult stem cells

Patent Number: 7,259,011
This patent covers a stem cell that is positive for expression of CD13, CD34, CD56 and CD117, negative for CD10. Dependent claims further cover the phenotype of CD2, CD5, CD14, CD19, CD33, CD45, and DRII negative, CD13,CD34, CD56, CD90, CD117 positive, and CD2, CD3, CD10, CD14, CD16, CD31, CD33, CD45 and CD64 negative. The stem cell can be derived from the muscle or bone marrow. The...
Inventors: Lucas; Paul (Poughkeepsie, NY), Schultz; Sherri (Katonah, NY), Pine; Sharon P. (Montgomery Village, MD)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday May 20th, 2004

Method of treating mood disorders and/or anxiety disorders by brain stimulation

Patent Number: 7,313,442
While studies have already demonstrated the ability of adult stem cells and embryonic stem cells to differentiate into neurons, the possibility of modulating new neurons to integrate into existing neurons, as well as enhance activity, is the philosophical "next...
Inventors: Velasco; Francisco (Mexico City, MX), Jimenez; Fiacro (Col. Roma, MX), Velasco; Marcos (Mexico City, MX), Lozano; Andres M. (Toronto, CA)
Assignee: Advanced Neuromodulation Systems, Inc. (Plano, TX)
Date of First Priority Issue: Friday April 30th, 2004

Method of expanding and differentiating cord blood cells by hyperthermic incubation

Patent Number: 7,452,662
The stem cell compartment is part of a physiological system that responds to various stimuli.  For example, during infections, the hematopoietic stem cells produce more granulocytes to fight off the sickness, or during periods of hypoxia (such as living on a mountain), they produce more erythrocytes.  Inventors have used the physiological context of stem cells to come up with new...
Inventors: Dupuis; Nicolas (Quebec, CA), Proulx; Chantal (Sainte-Foy, CA)
Assignee: Hema-Quebec (Saint-Laurent, CA)
Date of First Priority Issue: Friday April 23rd, 2004

Use of Xenopus laevis oocytes a microincubators

Patent Number: 7,135,336
The concept of "de-differentiation" of cells is very attractive from a therapeutic perspective since it offers the possibility of generating autologous stem cells from somatic tissue. If one could devise a method for generating even minute numbers of totipotent stem cells from autologous tissue, these cells could be expanded and used to treat almost any illness. The use of nuclear transfer for...
Inventors: Paylian; Sergei (Knoxville, TN)
Assignee: University of South Florida (Tampa, FL)
Date of First Priority Issue: Wednesday April 21st, 2004

Direct differentiation method for making cardiomyocytes from human embryonic stem cells

Patent Number: 7,452,718
One of the important areas of research in embryonic stem cells involves design of novel ways to upscale production of differentiated cells.  Another important area is developing cells that may be used clinically.  The company Novocell, for example, has developed various systems of expanding embryonic stem cells without the use of mouse feeder...
Inventors: Gold; Joseph D. (San Francisco, CA), Hassanipour; Mohammad (Danville, CA), Collins; Lila R. (Fremont, CA), Xu; Chunhui (Palo Alto, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Friday March 26th, 2004

Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments

Patent Number: 7,176,231
Although much effort in stem cell therapeutic development is being focused on administration of exogenous stem cells, one area that is generally being overlooked is methods of activating/expanding endogenous stem cells. It was recently published that the in vivo inhibition of the enzyme GSK-3 promotes hematopoietic stem cell self renewal (Trowbridge et al. Glycogen synthase kinase-3 is an in vivo...
Inventors: Heckel; Armin (Biberach, DE), Roth; Gerald Juergen (Biberach, DE), Kley; Joerg (Mittelbiberach, DE), Hoerer; Stefan (Ochsenhausen, DE), Uphues; Ingo (Ummendorf, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim, DE)
Date of First Priority Issue: Friday March 12th, 2004

Definitive endoderm

Patent Number: 7,510,876
Continuing Novocell's domination of IP in the area of developing commercial ES-derived products, this recent patent covers composition of matter on in vitro endoderm (eg progenitor cell of the liver, pancreas, digestive tube)  derived from "multipotent" cells.  The broadest claim, "An in vitro cell culture comprising human cells wherein at least 15% of said human cells are...
Inventors: D'Amour; Kevin Allen (San Diego, CA), Agulnick; Alan D. (San Marcos, CA), Baetge; Emmanuel E. (Encinitas, CA)
Assignee: Cythera, Inc. (San Diego, CA)
Date of First Priority Issue: Tuesday December 23rd, 2003

Methods for identifying factors for differentiating definitive endoderm

Patent Number: 7,541,185
Continuing its tradition of IP excellence, Novocell took a very interesting angle in the current patent.  Covered are tests for identifying factors that can induce stem cell differentiation into endoderm.The first independent claim is:" A method of identifying a factor that promotes the differentiation of human definitive endoderm cells, said method comprising the steps of: obtaining a...
Inventors: D'Amour; Kevin Allen (San Diego, CA), Agulnick; Alan D. (San Marcos, CA), Eliazer; Susan (San Diego, CA), Baetge; Emmanuel E. (Encinitas, CA)
Assignee: Cythera, Inc. (San Diego, CA)
Date of First Priority Issue: Tuesday December 23rd, 2003

Modified hyaluronic acid for use in musculoskeletal tissue repair

Patent Number: 7091191
This patent is useful for making scaffolds onto which stem cells, progenitor cells, or other type of cells can be seeded, and the scaffold together with the seeded cells are implanted in vivo. Previous scaffold technologies using hyaluronic acid have the drawback of very rapid resorption in the body, not giving the cells enough time to integrate and function properly. This patent uses a novel...
Inventors: Laredo, Walter R. (Hillsborough, NJ); Rezania, Alireza (Hillsborough, NJ)
Assignee: Ethicon, Inc. (Somerville, NJ)
Date of First Priority Issue: Friday December 19th, 2003 1 Comment

Preparation of a cell concentrate from a physiological solution

Patent Number: 7,291,450
The use of bone marrow mononuclear cells as a source of stem cells has been widely described in numerous medical procedures ranging from stimulation of angiogenesis in patients with peripheral artery disease to treatment of terminal liver failure, to treatment of heart disease. Unfortunately the use of...
Inventors: Sowemimo-Coker; Samuel O. (Dix Hills, NY), Scott; Marcus Lee (Memphis, TN), Long; Marc (Memphis, TN), Margerrison; Ed (Germantown, TN), Cooper; Michael B. (Memphis, TN)
Assignee: Smith & Nephew, Inc. (Memphis, TN); Pall Corporation (East Hills, NY)
Date of First Priority Issue: Wednesday December 10th, 2003

Method for enhancing proliferation of bone marrow cells or spleen cells with an ethanol-insoluble extract of dioscorea

Patent Number: 7,419,690
There has been a great interest in patenting natural compounds and plant derivatives for manipulation of the stem cell compartment.  For example, there is an issued patent covering seaweed extract for mobilization of stem cells, pine cone extracts for dendritic cell differentiation, and now the use of Yam extracts for...
Inventors: Yang; Ning-Sun (Taipei, TW), Su; Pei-Fen (Keelong, TW), Li; Chin-Jin (Taipei, TW), Shyur; Lie-Fen (Taipei, TW)
Assignee: Academia Sinica (Taipei, TW)
Date of First Priority Issue: Monday December 1st, 2003

Reduction of dermal scarring

Patent Number: 7,465,442
TGF-beta is a multi-functioning cytokine with activities in a variety of physiological processes, including suppression of inflammation, protecting the bone marrow from stress, and stimulation of fibrosis.  TGF-beta is known to inhibit cell cycle progression in part by turning on p21.sup.WAF1/Cip1...
Inventors: Gu; Danling (San Diego, CA), Zepeda; Monica (San Diego, CA)
Assignee: Canji, Inc. (Palo Alto, CA)
Date of First Priority Issue: Monday November 24th, 2003

Conformable tissue repair implant capable of injection delivery

Patent Number: 7,316,822
This patent covers an implantable matrix that includes: a) the matrix itself; b) live cells; and c) tissue fragments. The matrix itself is made of granules which are resorbable and bear a specific size. The tissue fragments include cartilage, meniscus, tendon, ligament, dermis, bone, fat, and combinations thereof. The overall mixture may be injected for treatment of a variety of degenerative...
Inventors: Binette; Francois (Weymouth, MA), Hammer; Joseph J. (Bridgewater, NJ), Mukhopadhyay; Krish (Bridgewater, NJ), Rosenblatt; Joel (Watchung, NJ)
Assignee: Ethicon, Inc. (Somerville, NJ)
Date of First Priority Issue: Sunday November 23rd, 2003

Order by:
<< | < | 1 2 3 4 5 6 | > | >>

Home | News | Patents | Products | Jobs | Links | Search | Journal | RSS

About | Advisory Board | Newsletter | Advertise | Contact | Sitemap | Privacy Policy | Terms of Use

Copyright © 2006 - 2014 StemCellPatents.com - All rights reserved. - Toronto Web Design

StemCellPatents.com V2.04